or both – as well as ApoE4 status and geographical region. Clarity AD’s phase 3 primary endpoint was change from baseline at 18 months in the CDR-SB (Clinical Dementi Rating Sum of Boxes), the ...

I-PREDICT matched McKeown with nivolumab, a checkpoint inhibitor approved for advanced ... problems I can’t do anything about, such as the APOE4 gene, which elevates the risk of Alzheimer ...

The US Food and Drug Administration (FDA) has approved two types of drugs to treat the symptoms of Alzheimer’s disease namely Cholinesterase inhibitors ... In mice with APOE4, a genetic variant ...

"We'll start to get an idea of dose optimizing both [Elahere and IMGN-151] in combination with platinum-based chemo, bevacizumab, and PARP inhibitors ... developing its gene therapy candidate for ...

Scientists have discovered that inhaling xenon gas can activate brain immune cells to break down Alzheimer's-related plaques and reduce inflammation. Successful mouse experiments are paving the ...

Oct. 22, 2024 — Adults with type 2 diabetes on a low-carbohydrate diet may see benefits to their beta-cell function allowing them to better manage their disease and ... Oct. 17, 2024 ...

Edited by Anne C. Hart, Brown University, Providence, RI; received August 29, 2024; accepted December 19, 2024 by Editorial Board Member Yishi Jin Taken together, these results identify VHL-1 as a ...

bDepartment of Neurological Surgery, Malnati Brain Tumor Institute of the Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA cDepartment ...

State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...